Shares fell 6.0% after the earnings release, despite revenue exceeding management’s guidance. The transcript points to limited underlying growth—revenue rose 4% year over year and sequentially on a medical-only basis—and a slight sequential decline in average basket size as possible sources of investor disappointment; it does not disclose a specific guidance cut or margin deterioration.
Shares fell 2.8% as investors appeared cautious about the uncertain impact of the recent business deconsolidation and mixed signals on growth, despite stable revenue and margin performance in the core medical-only operations.